Changes

Jump to: navigation, search

Erdafitinib (Balversa)

66 bytes added, 8 January
m
History of changes in FDA indication
==History of changes in FDA indication==
*4/12/2019: [https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer Accelerated FDA approval] for "adult patients with locally advanced or metastatic [[Bladder_cancer|urothelial carcinoma]] that has susceptible [[Bioarkers#FGFR3 |FGFR3]] or [[Biomarkers#FGFR2 |FGFR2]] [[Biomarkers#Alterations|genetic alterations ]] and progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy."
==Also known as==
LookupUsers, editors, emailconfirmed
24,195
edits

Navigation menu